SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Rhea-AI Summary
Scienture (NASDAQ: SCNX) announced the commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and fulfillment of its first U.S. wholesaler purchase orders, marking nationwide distribution of its second FDA-approved commercial product.
REZENOPY™ is described as the highest-dose FDA-approved naloxone nasal spray in the U.S., delivering 10 mg in a single-use device for emergency treatment of known or suspected opioid overdose. According to Scienture, launch execution is supported by a dedicated national sales force, payer coverage potentially reaching more than 100 million covered lives, and GPO agreements providing commercial access to over 5,000 healthcare facilities, representing potential penetration of more than 60% of the U.S. institutional naloxone market. Based on IQVIA data (MAT June 2026), the U.S. naloxone market generated about $143 million in annual sales across roughly 9.8 million units, which Scienture highlights as a substantial commercial opportunity. The product is supplied as two single-spray intranasal devices per carton and includes detailed safety, administration, contraindication, and storage information.
Positive
- Commercial launch and first orders of REZENOPY™ Nasal Spray 10 mg in U.S.
- Second FDA-approved commercial product expands Scienture’s marketed portfolio
- U.S. naloxone market about $143 million annually across 9.8 million units
- Payer coverage with potential reach to more than 100 million covered lives
- GPO access to over 5,000 facilities, >60% of U.S. institutional naloxone market
Negative
- None.
News Explained
With REZENOPY™ now launched and initial wholesaler orders fulfilled, Scienture says its wholly owned subsidiary is commercializing it under exclusive U.S. rights from a
Market Reaction – SCNX
Following this news, SCNX has declined 1.00%, reflecting a mild negative market reaction. Argus tracked a peak move of +38.8% during the session. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner has triggered 62 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $0.41. Trading volume is exceptionally heavy at 3474.1x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 09 | Commercial readiness | Positive | +0.5% | Inventory completion and planned REZENOPY wholesaler shipments supported commercial availability. |
| Jun 18 | Access expansion | Positive | -1.6% | Expanded Arbli payer coverage added approximately 12.5 million covered lives nationwide. |
| Jun 09 | Formulary coverage | Positive | +4.0% | REZENOPY formulary inclusion and expanded institutional access preceded the commercial launch. |
| Jun 04 | Investor presentation | Neutral | +0.0% | Management scheduled a presentation and investor meetings at a New York City event. |
| Jun 02 | Patent grant | Positive | -1.4% | A U.S. patent covering REZENOPY was granted with protection described through 2041. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Commercial updates produced mixed historical outcomes, with positive reactions on some access announcements and divergence on others.
Key Terms
naloxone hydrochloride medical
opioid antagonist medical
group purchasing organization financial
central nervous system depression medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY™
Targeting continued commercial execution through the end of 2026 by expanding payer coverage, broadening product access, and increasing institutional adoption within the approximately
COMMACK, NY, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced the commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, including the fulfillment of its first purchase orders to U.S. pharmaceutical wholesalers. The milestone represents another important step in Scienture's commercial growth strategy as the Company expands its marketed product portfolio and begins nationwide distribution of its second FDA-approved commercial product.
REZENOPY™ is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, delivering 10 mg of naloxone hydrochloride in a single-use nasal spray device for the emergency treatment of known or suspected opioid overdose. Built on the proven naloxone molecule and a familiar nasal spray delivery platform, REZENOPY™ is designed to provide an important treatment option for overdoses involving highly potent synthetic opioids. According to IQVIA data (MAT June 2026), the U.S. naloxone market generated approximately
To support the launch, Scienture has deployed a dedicated national sales team focused on driving adoption across hospitals, emergency medical services (EMS), rehabilitation centers, pharmacies, public health agencies, and other key healthcare providers. REZENOPY™ is further supported by recently announced commercial payer coverage representing the potential to reach more than 100 million covered lives, as well as Group Purchasing Organization (GPO) agreements providing commercial access to more than 5,000 healthcare facilities, representing the potential to penetrate more than
“The commercial launch of REZENOPY™ represents another important milestone in our strategy to build a diversified portfolio of differentiated specialty pharmaceutical products,” said Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “Over the past year, we have focused on building the infrastructure required to support a successful launch, from manufacturing and supply chain readiness to distribution, market access, and commercial execution. As REZENOPY™ begins reaching customers nationwide, our focus is on driving adoption, expanding our commercial footprint, and establishing the product as another meaningful contributor to the Company's long-term focus on revenue growth.”
“The launch of REZENOPY™ represents an important step in the continued expansion of our commercial portfolio,” said Narasimhan Mani, President and Co-Chief Executive Officer of Scienture. “As our second FDA-approved commercial product, REZENOPY™ expands our portfolio of revenue-generating assets and leverages the commercial infrastructure we have established to support future growth. We believe REZENOPY's position as the highest-dose FDA-approved naloxone hydrochloride nasal spray, combined with broad institutional purchasing access, provide a strong foundation for market adoption. As we look to the balance of 2026, we remain focused on expanding market access catering to institutional utilization, in an attempt to maximize the product's commercial potential.”
As previously disclosed, Scienture, LLC, a wholly-owned subsidiary of Scienture Holdings, Inc., entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025, for the exclusive U.S. commercialization rights to REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, which received FDA approval on April 19, 2024.
About REZENOPY™
REZENOPY™ (naloxone hydrochloride) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT SAFETY INFORMATION
- Administration: REZENOPY™ nasal spray is for intranasal use only. Seek emergency medical care immediately after use. Administer a single spray into one nostril. If the patient does not respond within 2 to 3 minutes or responds and then relapses into respiratory depression, an additional dose may be given into the other nostril with a new device. Do not administer more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
- Contraindications: REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
- Warnings and Precautions:
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
- Adverse Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
- Storage and Handling: Store REZENOPY™ nasal spray in the blister and cartons provided. Store between 2°C to 25°C (36°F to 77°F). Excursions permitted up to 40°C (104°F). Do not freeze or expose to excessive heat above 40°C (104°F). Protect from light. REZENOPY™ nasal spray may freeze at cold temperatures. If this happens, the device will not spray. If REZENOPY™ nasal spray is frozen and is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.
For more detailed information, please refer to the full prescribing information provided by the FDA.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, such as REZENOPY™, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com
